Risk factors of heavy uterine bleeding in patients with endometriosis and adenomyosis treated with dienogest
article
OA: diamond
CC0
⤵ 7 in-corpus citations
AI-generated summary
Endometrioma was associated with reduced heavy uterine bleeding risk with dienogest, while uterine adenomyosis and specific uterine dimensions predicted increased risk.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
OBJECTIVE: Dienogest (DNG), a fourth-generation progestin, reduces pain associated with endometriosis and uterine adenomyosis; however, it is associated with irregular uterine bleeding that can cause anemia and poor quality of life. We investigated risk factors for heavy bleeding following DNG administration.
MATERIALS AND METHODS: We retrospectively investigated patients who received DNG for risk factors of heavy uterine bleeding, including clinical diagnosis, use of pretreatment gonadotropin-releasing hormone agonist, smoking, cancer antigen 125, and blood hormone levels. We additionally assessed the uterine area in patients with uterine adenomyosis, the major axis of the uterine body, the major axis of myometrial thickness, the site of tumor development, and the site of myoma development in patients with uterine fibroids.
RESULTS: Eighty Japanese patients were administered DNG. The median age was 41 (range: 24-51) years. The odds ratio (OR) for moderate-to-severe bleeding according to clinical diagnosis were 0.33 (P = 0.011) for endometrioma and 9.00 (P = 0.049) for uterine adenomyosis. Receiver operating characteristic curve analysis of the uterine area associated with uterine adenomyosis showed an area under the curve (AUC) of 0.909 between those with major and minor bleeding, with an optimal cut-off value of 7388.2 mm2. The uterine body major axis had an AUC of 0.946, with an optimal cut-off value of 78.3 mm. The major axis of myometrial thickness had an AUC of 0.855, with an optimal cut-off value of 46.8 mm.
CONCLUSION: Patients with endometrioma treated with DNG were less likely to experience heavy uterine bleeding. Uterine bleeding in patients with uterine adenomyosis and adenomyosis associated with uterine fibroids should be closely monitored while administering DNG.
My notes (saved in your browser only)
Condition tags
MeSH descriptors
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
References (24)
- Dienogest in long-term treatment of endometriosis via openalex
- Dienogest in long-term treatment of endometriosis via crossref
- Dienogest is a selective progesterone receptor agonist in transactivation analysis with potent oral endometrial activity due to its efficient pharmacokinetic profile via openalex
- Dienogest is a selective progesterone receptor agonist in transactivation analysis with potent oral endometrial activity due to its efficient pharmacokinetic profile via crossref
- Hormonal and histological study on irregular genital bleeding in patients with endometriosis during treatment with dienogest, a novel progestational therapeutic agent via crossref
- Long‐term dienogest administration in patients with symptomatic adenomyosis via openalex
- Long‐term dienogest administration in patients with symptomatic adenomyosis via crossref
- Long-term use of dienogest for the treatment of endometriosis via crossref
- Long‐term use of dienogest for the treatment of primary and secondary dysmenorrhea via openalex
- Long‐term use of dienogest for the treatment of primary and secondary dysmenorrhea via crossref
- Long-term use of dienogest in the treatment of painful symptoms in adenomyosis via crossref
- Maintenance therapy with dienogest following gonadotropin-releasing hormone agonist treatment for endometriosis-associated pelvic pain via openalex
- Maintenance therapy with dienogest following gonadotropin-releasing hormone agonist treatment for endometriosis-associated pelvic pain via crossref
- Reduced pelvic pain in women with endometriosis: efficacy of long-term dienogest treatment via openalex
- Reduced pelvic pain in women with endometriosis: efficacy of long-term dienogest treatment via crossref
- Risk factors of treatment discontinuation due to uterine bleeding in adenomyosis patients treated with dienogest via crossref
- Risk factors of treatment discontinuation due to uterine bleeding in adenomyosis patients treated with dienogest via openalex
- Subtype I (intrinsic) adenomyosis is an independent risk factor for dienogest-related serious unpredictable bleeding in patients with symptomatic adenomyosis via crossref
- Subtype I (intrinsic) adenomyosis is an independent risk factor for dienogest-related serious unpredictable bleeding in patients with symptomatic adenomyosis via openalex
- doi:10.2147/ijwh.s77202 via crossref
- W2045458073 via openalex
- W2079421112 via openalex
- W2080251208 via openalex
- W2739010978 via openalex
Cited by (8)
- Extracellular matrix deficiency contributes to irregular uterine bleeding following progestin therapy for adenomyosis 2026
- Risk factors and countermeasures for abnormal uterine bleeding during dienogest therapy for adenomyosis: a review 2025
- The effects of vaginal bromocriptine and dienogest on women with adenomyosis: a clinical study 2024
- Society of Endometriosis and Uterine Disorders forum: adenomyosis today, Paris, France, December 12, 2023 2024
- Endometriosis: A life-long journey to women 2024
- Heavy uterine bleeding in women with endometriosis and adenomyosis treated with dienogest 2024
- The use of dienogest in treatment of symptomatic adenomyosis: A systematic review and meta-analysis 2024
- Dienogest versus gonadotropin-releasing hormone analogues for the clinical treatment of endometriosis: an updated meta-analysis 2024
Source provenance
- crossref
- last seen: 2026-09-06T06:31:36.224860+00:00
- europepmc
- last seen: 2026-09-09T06:15:24.302764+00:00
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
- pubmed
- last seen: 2026-09-09T06:13:45.035851+00:00
License: CC0
· commercial use OK